AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12489980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg
Number of subjects: 24
Study 12489980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 24
Study 12489980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 24
Study 12489980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 8 mg (single dose)
Number of subjects: 24
Study 12489980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (repeated doses of 2-6 mg)
Number of subjects: 24
Study 12489980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (single and repeated doses)
Number of subjects: 24
Study 10474139 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated confidence intervals for a parameter
Number of subjects: 0
Study 10474139 — intervention group
Group type: EXPERIMENTAL
Intervention: General results in Hu and Lagakos
Number of subjects: 0
Study 8901152 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 12
Study 8901152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrazepam
Number of subjects: 12
Study 8901152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2004545 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide
Number of subjects: 30
Study 2004545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 6184780 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-amylase inhibitor
Number of subjects: 6
Study 31785251 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based 3D analyses
Number of subjects: 15
Study 31785251 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based cephalometric analyses
Number of subjects: 15
Study 31077640 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Ball (PB)
Number of subjects: 343
Study 27927064 — intervention group
Group type: EXPERIMENTAL
Intervention: Yingliu mixture combined with methimazole (Y-M), orally administered 25 mL three times daily for 12 weeks.
Number of subjects: 120
Study 27927064 — intervention group
Group type: COMPARATOR
Intervention: Methimazole alone, administered at 5-25 mg/day for 12 weeks.
Number of subjects: 120
Study 27927064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Y-M and methimazole)
Number of subjects: 120
Study 26004591 — intervention group
Group type: EXPERIMENTAL
Intervention: Water delivery
Number of subjects: 120
Study 26004591 — intervention group
Group type: COMPARATOR
Intervention: Traditional delivery
Number of subjects: 120
Study 24460309 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia combined with cisplatin chemotherapy and radiotherapy
Number of subjects: 154
Study 24460309 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia with T90 < 43°
Number of subjects: 154
Study 24460309 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia performed 4-10 times
Number of subjects: 154
Study 24460309 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia before or after radiotherapy
Number of subjects: 154
Study 24460309 — intervention group
Group type: COMPARATOR
Intervention: Control group (cisplatin chemotherapy and radiotherapy only)
Number of subjects: 154
Study 22263332 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (P2)
Number of subjects: 60
Study 22263332 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (P1)
Number of subjects: 60
Study 22263332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P3)
Number of subjects: 60
Study 19695548 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 198
Study 19695548 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 198
Study 16996857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 705
Study 16996857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 12699209 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective measures (visual analog scales)
Number of subjects: 100
Study 12699209 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measures (peak expiratory flow rates)
Number of subjects: 100
Study 12699209 — intervention group
Group type: COMPARATOR
Intervention: Sociodemographic features (poor and minority families)
Number of subjects: 100
Study 12699209 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's symptom accuracy
Number of subjects: 100
Study 10929034 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (ROAD-IN) consisting of ranimustine, vincristine, melphalan, dexamethasone, and interferon alpha (IFN-alpha) administered three times weekly for 3 weeks starting on day 22, repeated for three cycles.
Number of subjects: 161
Study 10929034 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (CR + PR) to induction therapy.
Number of subjects: 161
Study 10929034 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha (IFN-alpha) maintenance therapy.
Number of subjects: 161
Study 10929034 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to induction therapy.
Number of subjects: 161
Study 8985622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt to 90 degrees for 10 min (orthostatic hypotension)
Number of subjects: 86
Study 8985622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt to 90 degrees for 10 min (orthostatic tachycardia plus)
Number of subjects: 86
Study 8985622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt to 90 degrees for 30 min (vasovagal syncope)
Number of subjects: 86
Study 8985622 — intervention group
Group type: COMPARATOR
Intervention: Tilt to 60 degrees, 80 degrees, and 90 degrees for 20 min
Number of subjects: 86
Study 1458672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (400 mg/kg by i.v. infusion over 3 h)
Number of subjects: 31
Study 1458672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumen and sucrose by similar infusion)
Number of subjects: 31
Study 1458672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin and Placebo
Number of subjects: 31
Study 6747036 — intervention group
Group type: EXPERIMENTAL
Intervention: Two week program involving perspective-taking of social entities (friend, family, peer group, society)
Number of subjects: 87
Study 6747036 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised identity scale with discrepancy score measure
Number of subjects: 87
Study 30288761 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-Balance Ultrafiltration (Z-BUF) of priming blood
Number of subjects: 60
Study 29716192 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 15
Study 29716192 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 15
Study 29716192 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 15
Study 29716192 — intervention group
Group type: EXPERIMENTAL
Intervention: Camellia oil
Number of subjects: 15
Study 29716192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tallow
Number of subjects: 15
Study 29716192 — intervention group
Group type: COMPARATOR
Intervention: Control without oils
Number of subjects: 15
Study 27548794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 1.5 mg·kg
Number of subjects: 13
Study 27548794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3.0 mg·kg
Number of subjects: 13
Study 27548794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6.0 mg·kg
Number of subjects: 13
Study 27548794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27548794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (various doses)
Number of subjects: 13
Study 27548794 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 7.5 mg·kg
Number of subjects: 13
Study 24586912 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTI vaccine (25 µg)
Number of subjects: 95
Study 24586912 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTI vaccine (5 µg)
Number of subjects: 95
Study 24586912 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTI vaccine (50 µg)
Number of subjects: 95
Study 24586912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 21719717 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 100 mg once daily
Number of subjects: 120
Study 21719717 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg once daily
Number of subjects: 120
Study 21719717 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 600 mg once daily
Number of subjects: 120
Study 21719717 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 100 mg
Number of subjects: 120
Study 21719717 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 300 mg and 600 mg
Number of subjects: 120
Study 21719717 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-5334 (various doses)
Number of subjects: 120
Study 19926400 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (32 mg/day) and bupropion (360 mg/day) plus behavioral counseling
Number of subjects: 30
Study 16930857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 24 mg/day
Number of subjects: 76
Study 16930857 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 76
Study 16930857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16231757 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict treatment to maintain systolic BP below 140 mmHg (group A)
Number of subjects: 4320
Study 16231757 — intervention group
Group type: COMPARATOR
Intervention: Mild treatment to maintain systolic BP between 140 and below 160 mmHg (group B)
Number of subjects: 4320
Study 16231757 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoints (stroke, cardiac disease, vascular disease, renal failure)
Number of subjects: 4320
Study 11973014 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration with painful stimulation
Number of subjects: 0
Study 11973014 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effects established on remembered pain
Number of subjects: 0
Study 11973014 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal expectancy for drug efficacy and individual differences in suggestibility
Number of subjects: 0
Study 11973014 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent pain intensity and unpleasantness
Number of subjects: 0
Study 9989684 — intervention group
Group type: EXPERIMENTAL
Intervention: Test supplement (wheat fiber and protein)
Number of subjects: 24
Study 9989684 — intervention group
Group type: COMPARATOR
Intervention: Positive control (American Association of Cereal Chemists wheat bran supplement)
Number of subjects: 24
Study 9989684 — intervention group
Group type: COMPARATOR
Intervention: Negative control (1.7 g fiber/d)
Number of subjects: 24
Study 9989684 — intervention group
Group type: EXPERIMENTAL
Intervention: Test supplement
Number of subjects: 24
Study 7479629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (weight loss, reduced sodium and alcohol intake, increased physical activity)
Number of subjects: 902
Study 7479629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program
Number of subjects: 902
Study 2258026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) at dosage of 15 mg/kg/daily
Number of subjects: 112
Study 2258026 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) at dosage of 15 mg/kg/daily
Number of subjects: 112
Study 6998389 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical peritoneal debridement
Number of subjects: 0
Study 6998389 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical management
Number of subjects: 0
Study 31134315 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic signs of hook of hamate fracture
Number of subjects: 50
Study 31134315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring sign
Number of subjects: 50
Study 31134315 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique view
Number of subjects: 50
Study 31134315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral view
Number of subjects: 50
Study 29854166 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Case Demand Index (CCDI)
Number of subjects: 0
Study 29854166 — intervention group
Group type: COMPARATOR
Intervention: Existing workload measures
Number of subjects: 0
Study 25475901 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 VR colonoscopies (group I)
Number of subjects: 18
Study 25475901 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 VR colonoscopies (group II)
Number of subjects: 18
Study 23132875 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme 'Ready to Act' (12-week programme including 2 one-to-one and 8 group sessions, 18 hours total)
Number of subjects: 509
Study 23132875 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme 'Ready to Act'
Number of subjects: 509
Study 23132875 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 509
Study 21501336 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg oral baclofen
Number of subjects: 15
Study 21501336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18984660 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation
Number of subjects: 24
Study 18984660 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human IGF‐I injections
Number of subjects: 24
Study 17303495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg plus sublingual misoprostol 600 microg before D&E
Number of subjects: 900
Study 17303495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg plus vaginal misoprostol 600 microg before D&E
Number of subjects: 900
Study 17303495 — intervention group
Group type: COMPARATOR
Intervention: Sublingual misoprostol 600 microg before D&E
Number of subjects: 900
Study 17303495 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 600 microg before D&E
Number of subjects: 900
Study 15079132 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension induced by thoracic epidural anaesthesia (Group T)
Number of subjects: 36
Study 15079132 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal anesthesia (Group K)
Number of subjects: 36
Study 11796079 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 sessions of group music therapy
Number of subjects: 18
Study 11796079 — intervention group
Group type: COMPARATOR
Intervention: Control (no group music therapy)
Number of subjects: 18
Study 9401647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose loading
Number of subjects: 0
Study 8017669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with hyperbaric bupivacaine 0.5% (0.08 mg.cm‐1 of height)
Number of subjects: 20
Study 8017669 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with a bolus dose of 0.5% plain bupivacaine followed by continuous infusion
Number of subjects: 20
Study 8017669 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 20
Study 8017669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 20
Study 3320184 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118551
Number of subjects: 11
Study 3320184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3320184 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 11
Study 31360882 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized breast cancer screening (biannually, annually, biennially, or not at all depending on risk and age)
Number of subjects: 65000
Study 31360882 — intervention group
Group type: COMPARATOR
Intervention: Annual breast cancer screening
Number of subjects: 65000
Study 27570089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg oral daily
Number of subjects: 116
Study 27570089 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 116
Study 25344270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2)
Number of subjects: 11
Study 25344270 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (21% O2)
Number of subjects: 11
Study 22104960 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp with MC‐CM (70 mL of 300 mgI/mL)
Number of subjects: 90
Study 22104960 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp with HC‐CM (70 mL of 370 mg iodine/mL)
Number of subjects: 90
Study 22104960 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kVp with MC‐CM
Number of subjects: 90
Study 21432599 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal breakfast
Number of subjects: 150
Study 21432599 — intervention group
Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 150
Study 18457338 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly maintenance Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study 18457338 — intervention group
Group type: COMPARATOR
Intervention: Supportive clinical management (CM)
Number of subjects: 0
Study 16156350 — intervention group
Group type: EXPERIMENTAL
Intervention: New spatio-temporal elastic registration algorithm for motion reconstruction from ultrasound sequences.
Number of subjects: 0
Study 16156350 — intervention group
Group type: COMPARATOR
Intervention: Previous method based on pairwise registration of consecutive frames.
Number of subjects: 0
Study 12757993 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of clinical equipoise and its acceptance
Number of subjects: 21
Study 12757993 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of randomization principles (chance and comparison)
Number of subjects: 21
Study 12757993 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in clinical equipoise
Number of subjects: 21
Study 12757993 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial information provision
Number of subjects: 21
Study 10491544 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-agent chemotherapy and irradiation to the primary tumor volume
Number of subjects: 213
Study 10491544 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone injections
Number of subjects: 213
Study 10491544 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructive surgery
Number of subjects: 213
Study 10491544 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 213
Study 8946439 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 40 mg and placebo (Group I, n = 13)
Number of subjects: 33
Study 8946439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg plus dexfenfluramine 15 mg at night (Group II, n = 20)
Number of subjects: 33
Study 1934527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms, orally)
Number of subjects: 8
Study 1934527 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of GRF 1‐29 (0.3 micrograms/kg/h)
Number of subjects: 8
Study 1934527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine pretreatment with GRF infusion
Number of subjects: 8
Study 1934527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6285533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A plus prednisone
Number of subjects: 100
Study 6285533 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (antilymphoblast globulin, prednisone, and azathioprine)
Number of subjects: 100
Study 6695663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6695663 — intervention group
Group type: COMPARATOR
Intervention: Control exercise tests on days 1 and 2
Number of subjects: 23
Study 29170030 — intervention group
Group type: EXPERIMENTAL
Intervention: $2 incentive
Number of subjects: 1688
Study 29170030 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery participation
Number of subjects: 1688
Study 29170030 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 1688
Study 26910672 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-based thermoplastic splint
Number of subjects: 40
Study 26910672 — intervention group
Group type: COMPARATOR
Intervention: Ulnar gutter splint
Number of subjects: 40
Study 26910672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24189519 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofilter
Number of subjects: 159
Study 24189519 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study 22327574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% TC
Number of subjects: 75
Study 22327574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% TC
Number of subjects: 75
Study 22327574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% EG
Number of subjects: 75
Study 22327574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% EG
Number of subjects: 75
Study 22327574 — intervention group
Group type: EXPERIMENTAL
Intervention: EG supplementation
Number of subjects: 75
Study 22327574 — intervention group
Group type: COMPARATOR
Intervention: Negative control (‐ve S. Enteritidis, ‐ve TC, or EG)
Number of subjects: 75
Study 22327574 — intervention group
Group type: COMPARATOR
Intervention: Compound control (‐ve S. Enteritidis, +ve 0.75% TC or 1% EG)
Number of subjects: 75
Study 22327574 — intervention group
Group type: COMPARATOR
Intervention: Positive control (+ve S. Enteritidis, ‐ve TC, or EG)
Number of subjects: 75
Study 22327574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose treatment (+ve S. Enteritidis, +ve 0.5% TC, or 0.75% EG)
Number of subjects: 75
Study 22327574 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment (+ve S. Enteritidis, +ve 0.75% TC, or 1% EG)
Number of subjects: 75
Study 19793085 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with additional allergen and trigger identification and avoidance advice
Number of subjects: 214
Study 19793085 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 18553245 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically occupationally orientated rehabilitation (MBO)
Number of subjects: 0
Study 18553245 — intervention group
Group type: COMPARATOR
Intervention: Standard medical rehabilitation
Number of subjects: 0